Spondyloarthritis & psoriatic arthritis

Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloartwhritis: cross-sectional analysis in the OASIS cohort

RMD OpenPublished Cross-sectional study

Authors' conclusion

The recommended Assessment of SpondyloArthritis international Society Core Outcome Set (ASAS-COS) pain measurement instrument total back pain BASDAI-Q2 has the best known group discrimination. For MS, the ASAS-COS stiffness measure (MS-severity/duration) performs well although MS-severity even slightly better. Known group discrimination is overall stable across CFs.

Study context

Population
Patients with r-axSpA with 8-year data from the OASIS cohort (mean age 54, 71% males)
Participants
85 patients
Exposure
Three pain and three morning stiffness measurement instruments, compared on construct validity
Outcome
Construct validity: correlation hypotheses and known-group discrimination (SMD across external constructs)
Methodological detailsOASIS cohort, known-group discrimination
  • OASIS cohort
  • Known-group discrimination

Main finding

As reported in the abstract

Known-group discrimination, SMD for external construct Axial Spondyloarthritis Disease Activity Score (ASDAS) (≥2.1 vs <2.1)

BASDAI-Q2

1.87

SMD

Total back pain

1.56

SMD

Back pain at night

1.07

SMD

Morning stiffness (MS)-severity

1.51

SMD

MS-severity/duration

1.39

SMD

MS-duration

1.16

SMD

Observational data: associations, not effects.

Further findings

Influence of contextual factors on known-group discrimination

Influence of contextual factors (CFs) on known group discrimination was limited

Original publication

Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloartwhritis: cross-sectional analysis in the OASIS cohort. RMD Open. Published 10 December 2024. doi:10.1136/rmdopen-2024-004775

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.